Power Injection Infusion Comprehensive Study by Type (Single Lumen Catheter Systems, Double Lumen Catheter Systems), Stroke (Cardiovascular Diseases, Cancer, Vascular Diseases, Physical Injuries, Digestive Disorders), End-User (Hospitals, Ambulatory Surgical Centres, Diagnostics Laboratories, Interventional Radiology Centres, Others), Modality (Attachable Catheters, Pre-Attached Catheters, Indication) Players and Region - Global Market Outlook to 2027

Power Injection Infusion Market by XX Submarkets | Forecast Years 2022-2027  

  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
About Power Injection Infusion
Power injection infusion is used for injecting contrast media into the bloodstream that additionally allows visualization for diagnosing using x-ray, computed tomography, resonance, and different medical imaging modality. Power injection infusion facilitates consistent flow rate and volume of targeted distinction media within the targeted space throughout medical imaging. This enables better image and maximum improvement during a little period of your time. Per the Centres for disease control and prevention (CDC), in 2018 there have been calculable 795,000 suffered from the stroke within the U.S.

AttributesDetails
Study Period2017-2027
Base Year2021
UnitValue (USD Million)


With the increased research and development in the field of power injection infusion, there are countries ruling the market and will be ruling in the coming decade. The high rate of prevalence of cardiovascular disease and cancer increases the demand for the power injection infusion market. The increasing number of domestic players is increasing the competition in the market. Analyst at AMA Research estimates that United States Players will contribute the maximum growth to Global Power Injection Infusion market throughout the forecasted period. Established and emerging Players should take a closer view at their existing organizations and reinvent traditional business and operating models to adapt to the future.

Becton Dickinson and Company (United States), Smiths Medical Inc. (United States), B. Braun Medical Inc. (United States), Bayer Healthcare (Germany), TekMed Pty Ltd. (Australia), Covidien (Ireland), AngioDynamics (United States), Bracco S.p.A (Italy), Medtron AG (United States), Nemoto Kyorindo Co. Ltd. (Japan) and Ulrich GmBH (Germany) are some of the key players that are part of study coverage.

Segmentation Overview
AMA Research has segmented the market of Global Power Injection Infusion market by Type (Single Lumen Catheter Systems and Double Lumen Catheter Systems) and Region.



On the basis of geography, the market of Power Injection Infusion has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by Stroke, the sub-segment i.e. Cardiovascular Diseases will boost the Power Injection Infusion market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by End-User, the sub-segment i.e. Hospitals will boost the Power Injection Infusion market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Modality, the sub-segment i.e. Attachable Catheters will boost the Power Injection Infusion market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Power Injection Infusion Market Dynamics:
AttributesDetails
Growth Drivers
  • Increasing Prevalence of Cardiovascular Heart Disorders
  • The Rise in Geriatric Population
Influencing Trends
  • Adoption of Interventional Radiology Procedures
Restraints
  • Delay of Manufacturing Activities
  • Fluctuating Price of Raw Materials
Road Blocks / Challenges
  • Increasing Number of Players in The Market Creating Competition
Gaps & Opportunities
  • Advancement of Technology
  • Increasing New Product Development and Approvals by The Leading Innovative Players


In 2017 Bayer launched its Medrad MRXperion, a magnetic resonance injection system after receiving approval from U. S. Food and Drug Administration (FDA).


Key Target Audience
New Entrants/Investors, Analysts and Strategic Business Planners, Providers of Power Injection Infusion, Venture Capitalists and Private Equity Firms and End-Use Industry

About Approach
To evaluate and validate the market size various sources including primary and secondary analysis is utilized. AMA Research follows regulatory standards such as NAICS/SIC/ICB/TRCB, to have a better understanding of the market. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with the purpose to understand the companies positioning regarding the market value, volume, and their market share for regional as well as global.

Further to bring relevance specific to any niche market we set and apply a number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Agencies) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders, etc., and work towards appointment generation.

The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, the analyst team keeps preparing a set of questionnaires, and after getting the appointee list; the target audience is then tapped and segregated with various mediums and channels that are feasible for making connections that including email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey, etc.

Report Objectives / Segmentation Covered

By Type
  • Single Lumen Catheter Systems
  • Double Lumen Catheter Systems
By Stroke
  • Cardiovascular Diseases
  • Cancer
  • Vascular Diseases
  • Physical Injuries
  • Digestive Disorders

By End-User
  • Hospitals
  • Ambulatory Surgical Centres
  • Diagnostics Laboratories
  • Interventional Radiology Centres
  • Others

By Modality
  • Attachable Catheters
  • Pre-Attached Catheters
  • Indication

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increasing Prevalence of Cardiovascular Heart Disorders
      • 3.2.2. The Rise in Geriatric Population
    • 3.3. Market Challenges
      • 3.3.1. Increasing Number of Players in The Market Creating Competition
    • 3.4. Market Trends
      • 3.4.1. Adoption of Interventional Radiology Procedures
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Power Injection Infusion, by Type, Stroke, End-User, Modality and Region (value and price ) (2016-2021)
    • 5.1. Introduction
    • 5.2. Global Power Injection Infusion (Value)
      • 5.2.1. Global Power Injection Infusion by: Type (Value)
        • 5.2.1.1. Single Lumen Catheter Systems
        • 5.2.1.2. Double Lumen Catheter Systems
      • 5.2.2. Global Power Injection Infusion by: Stroke (Value)
        • 5.2.2.1. Cardiovascular Diseases
        • 5.2.2.2. Cancer
        • 5.2.2.3. Vascular Diseases
        • 5.2.2.4. Physical Injuries
        • 5.2.2.5. Digestive Disorders
      • 5.2.3. Global Power Injection Infusion by: End-User (Value)
        • 5.2.3.1. Hospitals
        • 5.2.3.2. Ambulatory Surgical Centres
        • 5.2.3.3. Diagnostics Laboratories
        • 5.2.3.4. Interventional Radiology Centres
        • 5.2.3.5. Others
      • 5.2.4. Global Power Injection Infusion by: Modality (Value)
        • 5.2.4.1. Attachable Catheters
        • 5.2.4.2. Pre-Attached Catheters
        • 5.2.4.3. Indication
      • 5.2.5. Global Power Injection Infusion Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. South Korea
          • 5.2.5.2.5. Taiwan
          • 5.2.5.2.6. Australia
          • 5.2.5.2.7. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Italy
          • 5.2.5.3.4. United Kingdom
          • 5.2.5.3.5. Netherlands
          • 5.2.5.3.6. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
    • 5.3. Global Power Injection Infusion (Price)
      • 5.3.1. Global Power Injection Infusion by: Type (Price)
  • 6. Power Injection Infusion: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2021)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Becton Dickinson and Company (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Smiths Medical Inc. (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. B. Braun Medical Inc. (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Bayer Healthcare (Germany)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. TekMed Pty Ltd. (Australia)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Covidien (Ireland)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. AngioDynamics (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Bracco S.p.A (Italy)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Medtron AG (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Nemoto Kyorindo Co. Ltd. (Japan)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
      • 6.4.11. Ulrich GmBH (Germany)
        • 6.4.11.1. Business Overview
        • 6.4.11.2. Products/Services Offerings
        • 6.4.11.3. Financial Analysis
        • 6.4.11.4. SWOT Analysis
  • 7. Global Power Injection Infusion Sale, by Type, Stroke, End-User, Modality and Region (value and price ) (2022-2027)
    • 7.1. Introduction
    • 7.2. Global Power Injection Infusion (Value)
      • 7.2.1. Global Power Injection Infusion by: Type (Value)
        • 7.2.1.1. Single Lumen Catheter Systems
        • 7.2.1.2. Double Lumen Catheter Systems
      • 7.2.2. Global Power Injection Infusion by: Stroke (Value)
        • 7.2.2.1. Cardiovascular Diseases
        • 7.2.2.2. Cancer
        • 7.2.2.3. Vascular Diseases
        • 7.2.2.4. Physical Injuries
        • 7.2.2.5. Digestive Disorders
      • 7.2.3. Global Power Injection Infusion by: End-User (Value)
        • 7.2.3.1. Hospitals
        • 7.2.3.2. Ambulatory Surgical Centres
        • 7.2.3.3. Diagnostics Laboratories
        • 7.2.3.4. Interventional Radiology Centres
        • 7.2.3.5. Others
      • 7.2.4. Global Power Injection Infusion by: Modality (Value)
        • 7.2.4.1. Attachable Catheters
        • 7.2.4.2. Pre-Attached Catheters
        • 7.2.4.3. Indication
      • 7.2.5. Global Power Injection Infusion Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. South Korea
          • 7.2.5.2.5. Taiwan
          • 7.2.5.2.6. Australia
          • 7.2.5.2.7. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Italy
          • 7.2.5.3.4. United Kingdom
          • 7.2.5.3.5. Netherlands
          • 7.2.5.3.6. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
    • 7.3. Global Power Injection Infusion (Price)
      • 7.3.1. Global Power Injection Infusion by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Power Injection Infusion: by Type(USD Million)
  • Table 2. Power Injection Infusion Single Lumen Catheter Systems , by Region USD Million (2016-2021)
  • Table 3. Power Injection Infusion Double Lumen Catheter Systems , by Region USD Million (2016-2021)
  • Table 4. Power Injection Infusion: by Stroke(USD Million)
  • Table 5. Power Injection Infusion Cardiovascular Diseases , by Region USD Million (2016-2021)
  • Table 6. Power Injection Infusion Cancer , by Region USD Million (2016-2021)
  • Table 7. Power Injection Infusion Vascular Diseases , by Region USD Million (2016-2021)
  • Table 8. Power Injection Infusion Physical Injuries , by Region USD Million (2016-2021)
  • Table 9. Power Injection Infusion Digestive Disorders , by Region USD Million (2016-2021)
  • Table 10. Power Injection Infusion: by End-User(USD Million)
  • Table 11. Power Injection Infusion Hospitals , by Region USD Million (2016-2021)
  • Table 12. Power Injection Infusion Ambulatory Surgical Centres , by Region USD Million (2016-2021)
  • Table 13. Power Injection Infusion Diagnostics Laboratories , by Region USD Million (2016-2021)
  • Table 14. Power Injection Infusion Interventional Radiology Centres , by Region USD Million (2016-2021)
  • Table 15. Power Injection Infusion Others , by Region USD Million (2016-2021)
  • Table 16. Power Injection Infusion: by Modality(USD Million)
  • Table 17. Power Injection Infusion Attachable Catheters , by Region USD Million (2016-2021)
  • Table 18. Power Injection Infusion Pre-Attached Catheters , by Region USD Million (2016-2021)
  • Table 19. Power Injection Infusion Indication , by Region USD Million (2016-2021)
  • Table 20. South America Power Injection Infusion, by Country USD Million (2016-2021)
  • Table 21. South America Power Injection Infusion, by Type USD Million (2016-2021)
  • Table 22. South America Power Injection Infusion, by Stroke USD Million (2016-2021)
  • Table 23. South America Power Injection Infusion, by End-User USD Million (2016-2021)
  • Table 24. South America Power Injection Infusion, by Modality USD Million (2016-2021)
  • Table 25. Brazil Power Injection Infusion, by Type USD Million (2016-2021)
  • Table 26. Brazil Power Injection Infusion, by Stroke USD Million (2016-2021)
  • Table 27. Brazil Power Injection Infusion, by End-User USD Million (2016-2021)
  • Table 28. Brazil Power Injection Infusion, by Modality USD Million (2016-2021)
  • Table 29. Argentina Power Injection Infusion, by Type USD Million (2016-2021)
  • Table 30. Argentina Power Injection Infusion, by Stroke USD Million (2016-2021)
  • Table 31. Argentina Power Injection Infusion, by End-User USD Million (2016-2021)
  • Table 32. Argentina Power Injection Infusion, by Modality USD Million (2016-2021)
  • Table 33. Rest of South America Power Injection Infusion, by Type USD Million (2016-2021)
  • Table 34. Rest of South America Power Injection Infusion, by Stroke USD Million (2016-2021)
  • Table 35. Rest of South America Power Injection Infusion, by End-User USD Million (2016-2021)
  • Table 36. Rest of South America Power Injection Infusion, by Modality USD Million (2016-2021)
  • Table 37. Asia Pacific Power Injection Infusion, by Country USD Million (2016-2021)
  • Table 38. Asia Pacific Power Injection Infusion, by Type USD Million (2016-2021)
  • Table 39. Asia Pacific Power Injection Infusion, by Stroke USD Million (2016-2021)
  • Table 40. Asia Pacific Power Injection Infusion, by End-User USD Million (2016-2021)
  • Table 41. Asia Pacific Power Injection Infusion, by Modality USD Million (2016-2021)
  • Table 42. China Power Injection Infusion, by Type USD Million (2016-2021)
  • Table 43. China Power Injection Infusion, by Stroke USD Million (2016-2021)
  • Table 44. China Power Injection Infusion, by End-User USD Million (2016-2021)
  • Table 45. China Power Injection Infusion, by Modality USD Million (2016-2021)
  • Table 46. Japan Power Injection Infusion, by Type USD Million (2016-2021)
  • Table 47. Japan Power Injection Infusion, by Stroke USD Million (2016-2021)
  • Table 48. Japan Power Injection Infusion, by End-User USD Million (2016-2021)
  • Table 49. Japan Power Injection Infusion, by Modality USD Million (2016-2021)
  • Table 50. India Power Injection Infusion, by Type USD Million (2016-2021)
  • Table 51. India Power Injection Infusion, by Stroke USD Million (2016-2021)
  • Table 52. India Power Injection Infusion, by End-User USD Million (2016-2021)
  • Table 53. India Power Injection Infusion, by Modality USD Million (2016-2021)
  • Table 54. South Korea Power Injection Infusion, by Type USD Million (2016-2021)
  • Table 55. South Korea Power Injection Infusion, by Stroke USD Million (2016-2021)
  • Table 56. South Korea Power Injection Infusion, by End-User USD Million (2016-2021)
  • Table 57. South Korea Power Injection Infusion, by Modality USD Million (2016-2021)
  • Table 58. Taiwan Power Injection Infusion, by Type USD Million (2016-2021)
  • Table 59. Taiwan Power Injection Infusion, by Stroke USD Million (2016-2021)
  • Table 60. Taiwan Power Injection Infusion, by End-User USD Million (2016-2021)
  • Table 61. Taiwan Power Injection Infusion, by Modality USD Million (2016-2021)
  • Table 62. Australia Power Injection Infusion, by Type USD Million (2016-2021)
  • Table 63. Australia Power Injection Infusion, by Stroke USD Million (2016-2021)
  • Table 64. Australia Power Injection Infusion, by End-User USD Million (2016-2021)
  • Table 65. Australia Power Injection Infusion, by Modality USD Million (2016-2021)
  • Table 66. Rest of Asia-Pacific Power Injection Infusion, by Type USD Million (2016-2021)
  • Table 67. Rest of Asia-Pacific Power Injection Infusion, by Stroke USD Million (2016-2021)
  • Table 68. Rest of Asia-Pacific Power Injection Infusion, by End-User USD Million (2016-2021)
  • Table 69. Rest of Asia-Pacific Power Injection Infusion, by Modality USD Million (2016-2021)
  • Table 70. Europe Power Injection Infusion, by Country USD Million (2016-2021)
  • Table 71. Europe Power Injection Infusion, by Type USD Million (2016-2021)
  • Table 72. Europe Power Injection Infusion, by Stroke USD Million (2016-2021)
  • Table 73. Europe Power Injection Infusion, by End-User USD Million (2016-2021)
  • Table 74. Europe Power Injection Infusion, by Modality USD Million (2016-2021)
  • Table 75. Germany Power Injection Infusion, by Type USD Million (2016-2021)
  • Table 76. Germany Power Injection Infusion, by Stroke USD Million (2016-2021)
  • Table 77. Germany Power Injection Infusion, by End-User USD Million (2016-2021)
  • Table 78. Germany Power Injection Infusion, by Modality USD Million (2016-2021)
  • Table 79. France Power Injection Infusion, by Type USD Million (2016-2021)
  • Table 80. France Power Injection Infusion, by Stroke USD Million (2016-2021)
  • Table 81. France Power Injection Infusion, by End-User USD Million (2016-2021)
  • Table 82. France Power Injection Infusion, by Modality USD Million (2016-2021)
  • Table 83. Italy Power Injection Infusion, by Type USD Million (2016-2021)
  • Table 84. Italy Power Injection Infusion, by Stroke USD Million (2016-2021)
  • Table 85. Italy Power Injection Infusion, by End-User USD Million (2016-2021)
  • Table 86. Italy Power Injection Infusion, by Modality USD Million (2016-2021)
  • Table 87. United Kingdom Power Injection Infusion, by Type USD Million (2016-2021)
  • Table 88. United Kingdom Power Injection Infusion, by Stroke USD Million (2016-2021)
  • Table 89. United Kingdom Power Injection Infusion, by End-User USD Million (2016-2021)
  • Table 90. United Kingdom Power Injection Infusion, by Modality USD Million (2016-2021)
  • Table 91. Netherlands Power Injection Infusion, by Type USD Million (2016-2021)
  • Table 92. Netherlands Power Injection Infusion, by Stroke USD Million (2016-2021)
  • Table 93. Netherlands Power Injection Infusion, by End-User USD Million (2016-2021)
  • Table 94. Netherlands Power Injection Infusion, by Modality USD Million (2016-2021)
  • Table 95. Rest of Europe Power Injection Infusion, by Type USD Million (2016-2021)
  • Table 96. Rest of Europe Power Injection Infusion, by Stroke USD Million (2016-2021)
  • Table 97. Rest of Europe Power Injection Infusion, by End-User USD Million (2016-2021)
  • Table 98. Rest of Europe Power Injection Infusion, by Modality USD Million (2016-2021)
  • Table 99. MEA Power Injection Infusion, by Country USD Million (2016-2021)
  • Table 100. MEA Power Injection Infusion, by Type USD Million (2016-2021)
  • Table 101. MEA Power Injection Infusion, by Stroke USD Million (2016-2021)
  • Table 102. MEA Power Injection Infusion, by End-User USD Million (2016-2021)
  • Table 103. MEA Power Injection Infusion, by Modality USD Million (2016-2021)
  • Table 104. Middle East Power Injection Infusion, by Type USD Million (2016-2021)
  • Table 105. Middle East Power Injection Infusion, by Stroke USD Million (2016-2021)
  • Table 106. Middle East Power Injection Infusion, by End-User USD Million (2016-2021)
  • Table 107. Middle East Power Injection Infusion, by Modality USD Million (2016-2021)
  • Table 108. Africa Power Injection Infusion, by Type USD Million (2016-2021)
  • Table 109. Africa Power Injection Infusion, by Stroke USD Million (2016-2021)
  • Table 110. Africa Power Injection Infusion, by End-User USD Million (2016-2021)
  • Table 111. Africa Power Injection Infusion, by Modality USD Million (2016-2021)
  • Table 112. North America Power Injection Infusion, by Country USD Million (2016-2021)
  • Table 113. North America Power Injection Infusion, by Type USD Million (2016-2021)
  • Table 114. North America Power Injection Infusion, by Stroke USD Million (2016-2021)
  • Table 115. North America Power Injection Infusion, by End-User USD Million (2016-2021)
  • Table 116. North America Power Injection Infusion, by Modality USD Million (2016-2021)
  • Table 117. United States Power Injection Infusion, by Type USD Million (2016-2021)
  • Table 118. United States Power Injection Infusion, by Stroke USD Million (2016-2021)
  • Table 119. United States Power Injection Infusion, by End-User USD Million (2016-2021)
  • Table 120. United States Power Injection Infusion, by Modality USD Million (2016-2021)
  • Table 121. Canada Power Injection Infusion, by Type USD Million (2016-2021)
  • Table 122. Canada Power Injection Infusion, by Stroke USD Million (2016-2021)
  • Table 123. Canada Power Injection Infusion, by End-User USD Million (2016-2021)
  • Table 124. Canada Power Injection Infusion, by Modality USD Million (2016-2021)
  • Table 125. Mexico Power Injection Infusion, by Type USD Million (2016-2021)
  • Table 126. Mexico Power Injection Infusion, by Stroke USD Million (2016-2021)
  • Table 127. Mexico Power Injection Infusion, by End-User USD Million (2016-2021)
  • Table 128. Mexico Power Injection Infusion, by Modality USD Million (2016-2021)
  • Table 129. Power Injection Infusion: by Type(USD/Units)
  • Table 130. Company Basic Information, Sales Area and Its Competitors
  • Table 131. Company Basic Information, Sales Area and Its Competitors
  • Table 132. Company Basic Information, Sales Area and Its Competitors
  • Table 133. Company Basic Information, Sales Area and Its Competitors
  • Table 134. Company Basic Information, Sales Area and Its Competitors
  • Table 135. Company Basic Information, Sales Area and Its Competitors
  • Table 136. Company Basic Information, Sales Area and Its Competitors
  • Table 137. Company Basic Information, Sales Area and Its Competitors
  • Table 138. Company Basic Information, Sales Area and Its Competitors
  • Table 139. Company Basic Information, Sales Area and Its Competitors
  • Table 140. Company Basic Information, Sales Area and Its Competitors
  • Table 141. Power Injection Infusion: by Type(USD Million)
  • Table 142. Power Injection Infusion Single Lumen Catheter Systems , by Region USD Million (2022-2027)
  • Table 143. Power Injection Infusion Double Lumen Catheter Systems , by Region USD Million (2022-2027)
  • Table 144. Power Injection Infusion: by Stroke(USD Million)
  • Table 145. Power Injection Infusion Cardiovascular Diseases , by Region USD Million (2022-2027)
  • Table 146. Power Injection Infusion Cancer , by Region USD Million (2022-2027)
  • Table 147. Power Injection Infusion Vascular Diseases , by Region USD Million (2022-2027)
  • Table 148. Power Injection Infusion Physical Injuries , by Region USD Million (2022-2027)
  • Table 149. Power Injection Infusion Digestive Disorders , by Region USD Million (2022-2027)
  • Table 150. Power Injection Infusion: by End-User(USD Million)
  • Table 151. Power Injection Infusion Hospitals , by Region USD Million (2022-2027)
  • Table 152. Power Injection Infusion Ambulatory Surgical Centres , by Region USD Million (2022-2027)
  • Table 153. Power Injection Infusion Diagnostics Laboratories , by Region USD Million (2022-2027)
  • Table 154. Power Injection Infusion Interventional Radiology Centres , by Region USD Million (2022-2027)
  • Table 155. Power Injection Infusion Others , by Region USD Million (2022-2027)
  • Table 156. Power Injection Infusion: by Modality(USD Million)
  • Table 157. Power Injection Infusion Attachable Catheters , by Region USD Million (2022-2027)
  • Table 158. Power Injection Infusion Pre-Attached Catheters , by Region USD Million (2022-2027)
  • Table 159. Power Injection Infusion Indication , by Region USD Million (2022-2027)
  • Table 160. South America Power Injection Infusion, by Country USD Million (2022-2027)
  • Table 161. South America Power Injection Infusion, by Type USD Million (2022-2027)
  • Table 162. South America Power Injection Infusion, by Stroke USD Million (2022-2027)
  • Table 163. South America Power Injection Infusion, by End-User USD Million (2022-2027)
  • Table 164. South America Power Injection Infusion, by Modality USD Million (2022-2027)
  • Table 165. Brazil Power Injection Infusion, by Type USD Million (2022-2027)
  • Table 166. Brazil Power Injection Infusion, by Stroke USD Million (2022-2027)
  • Table 167. Brazil Power Injection Infusion, by End-User USD Million (2022-2027)
  • Table 168. Brazil Power Injection Infusion, by Modality USD Million (2022-2027)
  • Table 169. Argentina Power Injection Infusion, by Type USD Million (2022-2027)
  • Table 170. Argentina Power Injection Infusion, by Stroke USD Million (2022-2027)
  • Table 171. Argentina Power Injection Infusion, by End-User USD Million (2022-2027)
  • Table 172. Argentina Power Injection Infusion, by Modality USD Million (2022-2027)
  • Table 173. Rest of South America Power Injection Infusion, by Type USD Million (2022-2027)
  • Table 174. Rest of South America Power Injection Infusion, by Stroke USD Million (2022-2027)
  • Table 175. Rest of South America Power Injection Infusion, by End-User USD Million (2022-2027)
  • Table 176. Rest of South America Power Injection Infusion, by Modality USD Million (2022-2027)
  • Table 177. Asia Pacific Power Injection Infusion, by Country USD Million (2022-2027)
  • Table 178. Asia Pacific Power Injection Infusion, by Type USD Million (2022-2027)
  • Table 179. Asia Pacific Power Injection Infusion, by Stroke USD Million (2022-2027)
  • Table 180. Asia Pacific Power Injection Infusion, by End-User USD Million (2022-2027)
  • Table 181. Asia Pacific Power Injection Infusion, by Modality USD Million (2022-2027)
  • Table 182. China Power Injection Infusion, by Type USD Million (2022-2027)
  • Table 183. China Power Injection Infusion, by Stroke USD Million (2022-2027)
  • Table 184. China Power Injection Infusion, by End-User USD Million (2022-2027)
  • Table 185. China Power Injection Infusion, by Modality USD Million (2022-2027)
  • Table 186. Japan Power Injection Infusion, by Type USD Million (2022-2027)
  • Table 187. Japan Power Injection Infusion, by Stroke USD Million (2022-2027)
  • Table 188. Japan Power Injection Infusion, by End-User USD Million (2022-2027)
  • Table 189. Japan Power Injection Infusion, by Modality USD Million (2022-2027)
  • Table 190. India Power Injection Infusion, by Type USD Million (2022-2027)
  • Table 191. India Power Injection Infusion, by Stroke USD Million (2022-2027)
  • Table 192. India Power Injection Infusion, by End-User USD Million (2022-2027)
  • Table 193. India Power Injection Infusion, by Modality USD Million (2022-2027)
  • Table 194. South Korea Power Injection Infusion, by Type USD Million (2022-2027)
  • Table 195. South Korea Power Injection Infusion, by Stroke USD Million (2022-2027)
  • Table 196. South Korea Power Injection Infusion, by End-User USD Million (2022-2027)
  • Table 197. South Korea Power Injection Infusion, by Modality USD Million (2022-2027)
  • Table 198. Taiwan Power Injection Infusion, by Type USD Million (2022-2027)
  • Table 199. Taiwan Power Injection Infusion, by Stroke USD Million (2022-2027)
  • Table 200. Taiwan Power Injection Infusion, by End-User USD Million (2022-2027)
  • Table 201. Taiwan Power Injection Infusion, by Modality USD Million (2022-2027)
  • Table 202. Australia Power Injection Infusion, by Type USD Million (2022-2027)
  • Table 203. Australia Power Injection Infusion, by Stroke USD Million (2022-2027)
  • Table 204. Australia Power Injection Infusion, by End-User USD Million (2022-2027)
  • Table 205. Australia Power Injection Infusion, by Modality USD Million (2022-2027)
  • Table 206. Rest of Asia-Pacific Power Injection Infusion, by Type USD Million (2022-2027)
  • Table 207. Rest of Asia-Pacific Power Injection Infusion, by Stroke USD Million (2022-2027)
  • Table 208. Rest of Asia-Pacific Power Injection Infusion, by End-User USD Million (2022-2027)
  • Table 209. Rest of Asia-Pacific Power Injection Infusion, by Modality USD Million (2022-2027)
  • Table 210. Europe Power Injection Infusion, by Country USD Million (2022-2027)
  • Table 211. Europe Power Injection Infusion, by Type USD Million (2022-2027)
  • Table 212. Europe Power Injection Infusion, by Stroke USD Million (2022-2027)
  • Table 213. Europe Power Injection Infusion, by End-User USD Million (2022-2027)
  • Table 214. Europe Power Injection Infusion, by Modality USD Million (2022-2027)
  • Table 215. Germany Power Injection Infusion, by Type USD Million (2022-2027)
  • Table 216. Germany Power Injection Infusion, by Stroke USD Million (2022-2027)
  • Table 217. Germany Power Injection Infusion, by End-User USD Million (2022-2027)
  • Table 218. Germany Power Injection Infusion, by Modality USD Million (2022-2027)
  • Table 219. France Power Injection Infusion, by Type USD Million (2022-2027)
  • Table 220. France Power Injection Infusion, by Stroke USD Million (2022-2027)
  • Table 221. France Power Injection Infusion, by End-User USD Million (2022-2027)
  • Table 222. France Power Injection Infusion, by Modality USD Million (2022-2027)
  • Table 223. Italy Power Injection Infusion, by Type USD Million (2022-2027)
  • Table 224. Italy Power Injection Infusion, by Stroke USD Million (2022-2027)
  • Table 225. Italy Power Injection Infusion, by End-User USD Million (2022-2027)
  • Table 226. Italy Power Injection Infusion, by Modality USD Million (2022-2027)
  • Table 227. United Kingdom Power Injection Infusion, by Type USD Million (2022-2027)
  • Table 228. United Kingdom Power Injection Infusion, by Stroke USD Million (2022-2027)
  • Table 229. United Kingdom Power Injection Infusion, by End-User USD Million (2022-2027)
  • Table 230. United Kingdom Power Injection Infusion, by Modality USD Million (2022-2027)
  • Table 231. Netherlands Power Injection Infusion, by Type USD Million (2022-2027)
  • Table 232. Netherlands Power Injection Infusion, by Stroke USD Million (2022-2027)
  • Table 233. Netherlands Power Injection Infusion, by End-User USD Million (2022-2027)
  • Table 234. Netherlands Power Injection Infusion, by Modality USD Million (2022-2027)
  • Table 235. Rest of Europe Power Injection Infusion, by Type USD Million (2022-2027)
  • Table 236. Rest of Europe Power Injection Infusion, by Stroke USD Million (2022-2027)
  • Table 237. Rest of Europe Power Injection Infusion, by End-User USD Million (2022-2027)
  • Table 238. Rest of Europe Power Injection Infusion, by Modality USD Million (2022-2027)
  • Table 239. MEA Power Injection Infusion, by Country USD Million (2022-2027)
  • Table 240. MEA Power Injection Infusion, by Type USD Million (2022-2027)
  • Table 241. MEA Power Injection Infusion, by Stroke USD Million (2022-2027)
  • Table 242. MEA Power Injection Infusion, by End-User USD Million (2022-2027)
  • Table 243. MEA Power Injection Infusion, by Modality USD Million (2022-2027)
  • Table 244. Middle East Power Injection Infusion, by Type USD Million (2022-2027)
  • Table 245. Middle East Power Injection Infusion, by Stroke USD Million (2022-2027)
  • Table 246. Middle East Power Injection Infusion, by End-User USD Million (2022-2027)
  • Table 247. Middle East Power Injection Infusion, by Modality USD Million (2022-2027)
  • Table 248. Africa Power Injection Infusion, by Type USD Million (2022-2027)
  • Table 249. Africa Power Injection Infusion, by Stroke USD Million (2022-2027)
  • Table 250. Africa Power Injection Infusion, by End-User USD Million (2022-2027)
  • Table 251. Africa Power Injection Infusion, by Modality USD Million (2022-2027)
  • Table 252. North America Power Injection Infusion, by Country USD Million (2022-2027)
  • Table 253. North America Power Injection Infusion, by Type USD Million (2022-2027)
  • Table 254. North America Power Injection Infusion, by Stroke USD Million (2022-2027)
  • Table 255. North America Power Injection Infusion, by End-User USD Million (2022-2027)
  • Table 256. North America Power Injection Infusion, by Modality USD Million (2022-2027)
  • Table 257. United States Power Injection Infusion, by Type USD Million (2022-2027)
  • Table 258. United States Power Injection Infusion, by Stroke USD Million (2022-2027)
  • Table 259. United States Power Injection Infusion, by End-User USD Million (2022-2027)
  • Table 260. United States Power Injection Infusion, by Modality USD Million (2022-2027)
  • Table 261. Canada Power Injection Infusion, by Type USD Million (2022-2027)
  • Table 262. Canada Power Injection Infusion, by Stroke USD Million (2022-2027)
  • Table 263. Canada Power Injection Infusion, by End-User USD Million (2022-2027)
  • Table 264. Canada Power Injection Infusion, by Modality USD Million (2022-2027)
  • Table 265. Mexico Power Injection Infusion, by Type USD Million (2022-2027)
  • Table 266. Mexico Power Injection Infusion, by Stroke USD Million (2022-2027)
  • Table 267. Mexico Power Injection Infusion, by End-User USD Million (2022-2027)
  • Table 268. Mexico Power Injection Infusion, by Modality USD Million (2022-2027)
  • Table 269. Power Injection Infusion: by Type(USD/Units)
  • Table 270. Research Programs/Design for This Report
  • Table 271. Key Data Information from Secondary Sources
  • Table 272. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Power Injection Infusion: by Type USD Million (2016-2021)
  • Figure 5. Global Power Injection Infusion: by Stroke USD Million (2016-2021)
  • Figure 6. Global Power Injection Infusion: by End-User USD Million (2016-2021)
  • Figure 7. Global Power Injection Infusion: by Modality USD Million (2016-2021)
  • Figure 8. South America Power Injection Infusion Share (%), by Country
  • Figure 9. Asia Pacific Power Injection Infusion Share (%), by Country
  • Figure 10. Europe Power Injection Infusion Share (%), by Country
  • Figure 11. MEA Power Injection Infusion Share (%), by Country
  • Figure 12. North America Power Injection Infusion Share (%), by Country
  • Figure 13. Global Power Injection Infusion: by Type USD/Units (2016-2021)
  • Figure 14. Global Power Injection Infusion share by Players 2021 (%)
  • Figure 15. Global Power Injection Infusion share by Players (Top 3) 2021(%)
  • Figure 16. Global Power Injection Infusion share by Players (Top 5) 2021(%)
  • Figure 17. BCG Matrix for key Companies
  • Figure 18. Becton Dickinson and Company (United States) Revenue, Net Income and Gross profit
  • Figure 19. Becton Dickinson and Company (United States) Revenue: by Geography 2021
  • Figure 20. Smiths Medical Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 21. Smiths Medical Inc. (United States) Revenue: by Geography 2021
  • Figure 22. B. Braun Medical Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 23. B. Braun Medical Inc. (United States) Revenue: by Geography 2021
  • Figure 24. Bayer Healthcare (Germany) Revenue, Net Income and Gross profit
  • Figure 25. Bayer Healthcare (Germany) Revenue: by Geography 2021
  • Figure 26. TekMed Pty Ltd. (Australia) Revenue, Net Income and Gross profit
  • Figure 27. TekMed Pty Ltd. (Australia) Revenue: by Geography 2021
  • Figure 28. Covidien (Ireland) Revenue, Net Income and Gross profit
  • Figure 29. Covidien (Ireland) Revenue: by Geography 2021
  • Figure 30. AngioDynamics (United States) Revenue, Net Income and Gross profit
  • Figure 31. AngioDynamics (United States) Revenue: by Geography 2021
  • Figure 32. Bracco S.p.A (Italy) Revenue, Net Income and Gross profit
  • Figure 33. Bracco S.p.A (Italy) Revenue: by Geography 2021
  • Figure 34. Medtron AG (United States) Revenue, Net Income and Gross profit
  • Figure 35. Medtron AG (United States) Revenue: by Geography 2021
  • Figure 36. Nemoto Kyorindo Co. Ltd. (Japan) Revenue, Net Income and Gross profit
  • Figure 37. Nemoto Kyorindo Co. Ltd. (Japan) Revenue: by Geography 2021
  • Figure 38. Ulrich GmBH (Germany) Revenue, Net Income and Gross profit
  • Figure 39. Ulrich GmBH (Germany) Revenue: by Geography 2021
  • Figure 40. Global Power Injection Infusion: by Type USD Million (2022-2027)
  • Figure 41. Global Power Injection Infusion: by Stroke USD Million (2022-2027)
  • Figure 42. Global Power Injection Infusion: by End-User USD Million (2022-2027)
  • Figure 43. Global Power Injection Infusion: by Modality USD Million (2022-2027)
  • Figure 44. South America Power Injection Infusion Share (%), by Country
  • Figure 45. Asia Pacific Power Injection Infusion Share (%), by Country
  • Figure 46. Europe Power Injection Infusion Share (%), by Country
  • Figure 47. MEA Power Injection Infusion Share (%), by Country
  • Figure 48. North America Power Injection Infusion Share (%), by Country
  • Figure 49. Global Power Injection Infusion: by Type USD/Units (2022-2027)
List of companies from research coverage that are profiled in the study
  • Becton Dickinson and Company (United States)
  • Smiths Medical Inc. (United States)
  • B. Braun Medical Inc. (United States)
  • Bayer Healthcare (Germany)
  • TekMed Pty Ltd. (Australia)
  • Covidien (Ireland)
  • AngioDynamics (United States)
  • Bracco S.p.A (Italy)
  • Medtron AG (United States)
  • Nemoto Kyorindo Co. Ltd. (Japan)
  • Ulrich GmBH (Germany)
Select User Access Type

Key Highlights of Report


Aug 2022 170 Pages 72 Tables Base Year: 2021 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The standard version of the report profiles players such as Becton Dickinson and Company (United States), Smiths Medical Inc. (United States), B. Braun Medical Inc. (United States), Bayer Healthcare (Germany), TekMed Pty Ltd. (Australia), Covidien (Ireland), AngioDynamics (United States), Bracco S.p.A (Italy), Medtron AG (United States), Nemoto Kyorindo Co. Ltd. (Japan) and Ulrich GmBH (Germany) etc.
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.
"Adoption of Interventional Radiology Procedures" is seen as one of major influencing trends for Power Injection Infusion Market during projected period 2021-2027.
The Power Injection Infusion market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get a complete company list in our research coverage.

Know More About Global Power Injection Infusion Market Report?